Highwater Wealth Management LLC Takes $264,000 Position in Johnson & Johnson (JNJ)
Highwater Wealth Management LLC bought a new position in Johnson & Johnson (NYSE:JNJ) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,999 shares of the company’s stock, valued at approximately $264,000.
A number of other hedge funds have also recently modified their holdings of the stock. Lenox Wealth Advisors Inc. lifted its position in Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock worth $108,000 after purchasing an additional 6 shares during the period. Lbmc Investment Advisors LLC lifted its position in Johnson & Johnson by 0.4% in the first quarter. Lbmc Investment Advisors LLC now owns 3,704 shares of the company’s stock worth $461,000 after purchasing an additional 14 shares during the period. Berson & Corrado Investment Advisors LLC lifted its position in Johnson & Johnson by 0.7% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 2,835 shares of the company’s stock worth $353,000 after purchasing an additional 19 shares during the period. RB Capital Management LLC lifted its position in Johnson & Johnson by 0.4% in the first quarter. RB Capital Management LLC now owns 5,559 shares of the company’s stock worth $692,000 after purchasing an additional 24 shares during the period. Finally, Keel Point LLC lifted its position in Johnson & Johnson by 0.4% in the first quarter. Keel Point LLC now owns 6,402 shares of the company’s stock worth $797,000 after purchasing an additional 24 shares during the period. 65.90% of the stock is owned by hedge funds and other institutional investors.
Several research analysts recently commented on JNJ shares. BidaskClub raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Royal Bank Of Canada reissued a “buy” rating and set a $128.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 15th. Atlantic Securities cut Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price objective for the company. in a report on Friday, July 21st. Jefferies Group LLC reissued a “hold” rating and set a $145.00 price objective (up from $140.00) on shares of Johnson & Johnson in a report on Friday, July 14th. Finally, Morgan Stanley lifted their price objective on Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, July 5th. Five investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating to the stock. Johnson & Johnson presently has an average rating of “Hold” and a consensus price target of $135.29.
In other news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the transaction, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by company insiders.
Johnson & Johnson (JNJ) traded down 0.1661% during trading on Friday, hitting $131.5312. The stock had a trading volume of 1,579,699 shares. The company has a 50-day moving average of $132.79 and a 200 day moving average of $129.44. The company has a market cap of $353.03 billion, a price-to-earnings ratio of 22.2557 and a beta of 0.79. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.08. Johnson & Johnson also saw unusually large options trading on Wednesday. Stock investors purchased 11,192 put options on the company. This represents an increase of 244% compared to the average daily volume of 3,249 put options.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. During the same period last year, the company earned $1.74 earnings per share. The firm’s revenue was up 1.9% compared to the same quarter last year. On average, equities research analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were given a dividend of $0.84 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.52%. Johnson & Johnson’s dividend payout ratio (DPR) is 56.76%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.